FDA Was Already Investigating The Dipeptidyl Peptidase IV (DPP-IV) Inhibitor Class Of Diabetes Drugs For Kidney Or Renal Failure
(Posted by Tom Lamb at DrugInjuryWatch.com)
According to a new FDA quarterly report, "Potential Signals of Serious Risks / New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS): April - June 2017", a class of diabetes drugs referred to as dipeptidyl peptidase-4 inhibitors may be associated with rhabdomyolysis, a side effect which involves severe muscle damage.
In more detail, rhabdomyolysis is the breakdown of muscle tissue that leads to the release of muscle fiber contents into the blood. These substances are harmful to the kidney and often cause kidney damage.
This most recent FDA quarterly report was issued in early October 2017. It states that "FDA is evaluating the need for regulatory action" as regards this possible rhabdomyolysis side effect for these oral diabetes drugs:
Glyxambi (empagliflozin and linagliptin) tablets
Janumet (sitagliptin and metformin hydrochloride) tablets
Janumet XR (sitagliptin and metformin hydrochloride extended-release) tablets
Januvia (sitagliptin) tablets
Jentadueto (linagliptin and metformin hydrochloride) tablets
Jentadueto XR (linagliptin and metformin hydrochloride extended-release) tablets
Kazano (alogliptin and metformin hydrochloride) tablets
Kombiglyze XR (saxagliptin and metformin hydrochloride extended-release) tablets
Nesina (alogliptin) tablets
Onglyza (saxagliptin) tablets
Oseni (alogliptin and pioglitazone) tablets
Qtern (dapagliflozin and saxagliptin) tablets
Tradjenta (linagliptin) tablets
Diabetes Drugs Side Effects
Free Case Evaluation
Strictly Confidential, No Obligation.
Given this recent announce by the FDA, we will now be watching for reports of rhabdomyolysis in patients using Onglyza, Nesina, Januvia, and the other Type-2 diabetes drugs containing saxagliptin, alogliptin, sitagliptin, or linagliptin.
Previously the FDA had announced that it was evaluating the need for regulatory action for the dipeptidyl peptidase IV (DPP-IV) inhibitor class of diabetes medicines due to the serious side effect of renal failure, or kidney failure. To our knowledge, this evaluation by the FDA is ongoing now, in October 2017. See "Potential Signals of Serious Risks / New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS) between July – September 2015".
We will continue to watch for reports of kidney / renal failure in patients using Onglyza, Nesina, Januvia, and the other Type-2 diabetes drugs containing saxagliptin, alogliptin, sitagliptin, or linagliptin.
DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects (All website content by attorney Tom Lamb)
Drug Injury Case Evaluation - Free. Confidential. No Obligation. (Case review done by attorney Tom Lamb)